Annemilaï Tijeras‐Raballand

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study

Thierry André, Armand de Gramont, Déwi Vernerey et al. · Journal of Clinical Oncology · 2015 · 675 citations

Medicine, Molecular Genetics, Oncology +17

Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma

Cindy Neuzillet, Annemilaï Tijeras‐Raballand, Chanthirika Ragulan et al. · The Journal of Pathology · 2018 · 284 citations · Full text

Medicine, Cancer Biology, Oncology +15

Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

Sara Van de Veire, Ingeborg Stalmans, Femke Heindryckx et al. · Cell · 2010 · 253 citations · Full text

Medicine, Oncology, Pharmacology +14

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis

Lucile Astorgues‐Xerri, María E. Riveiro, Annemilaï Tijeras‐Raballand et al. · European Journal of Cancer · 2014 · 137 citations · Full text

Medicine, Oncology, Pharmacology +14

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in<i>ex vivo</i>whole tumor tissue samples from patients

Maria Serova, Annemilaï Tijeras‐Raballand, Célia Dos Santos et al. · Oncotarget · 2015 · 102 citations · Full text

Medicine, Oncology, Pharmacology +17